VistaGen Therapeutics, Inc.
VTGN
$0.24
-$0.01-2.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 217.42% | 53.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 217.42% | 53.47% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 217.42% | 53.47% | |||
| SG&A Expenses | -4.95% | -26.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.72% | -13.44% | |||
| Operating Income | 20.15% | 14.47% | |||
| Income Before Tax | 19.90% | 13.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.93% | 13.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.93% | 13.89% | |||
| EBIT | 20.15% | 14.47% | |||
| EBITDA | 20.22% | 14.50% | |||
| EPS Basic | 21.14% | 14.08% | |||
| Normalized Basic EPS | 21.11% | 14.12% | |||
| EPS Diluted | 21.14% | 14.08% | |||
| Normalized Diluted EPS | 21.11% | 14.12% | |||
| Average Basic Shares Outstanding | 1.54% | 0.23% | |||
| Average Diluted Shares Outstanding | 1.54% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||